SNDL

Company Overview — What Does SNDL Inc. Do?

Sundial Growers Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. SNDL Inc. (SNDL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Zachary R. George and employs approximately 580 people. With a market capitalization of $345M, SNDL is one of the notable companies in the Healthcare sector.

SNDL Inc. (SNDL) Stock Rating — Reduce (April 2026)

As of April 2026, SNDL Inc. receives a Reduce rating with a composite score of 35.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SNDL ranks #3,121 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SNDL Inc. ranks #457 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SNDL Stock Price and 52-Week Range

SNDL Inc. (SNDL) currently trades at $1.41. The stock gained $0.03 (2.2%) in the most recent trading session. The 52-week high for SNDL is $2.89, which means the stock is currently trading -51.2% from its annual peak. The 52-week low is $1.15, putting the stock 22.6% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is SNDL Overvalued or Undervalued? — Valuation Analysis

SNDL Inc. (SNDL) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.43x, versus the sector average of 2.75x. The price-to-sales ratio is 0.18x, compared to 1.66x for the average Healthcare stock.

At current multiples, SNDL Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

SNDL Inc. Profitability — ROE, Margins, and Quality Score

SNDL Inc. (SNDL) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -34.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -28.5% versus the sector average of -33.1%.

On a margin basis, SNDL Inc. reports gross margins of -17.1%, compared to 71.5% for the sector. The operating margin is -17.1% (sector: -66.1%). Net profit margin stands at -14.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SNDL Debt, Balance Sheet, and Financial Health

SNDL Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $121M. Cash and equivalents stand at $152M.

SNDL has a beta of 0.86, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for SNDL Inc. is 46/100, reflecting average volatility within the normal range for its sector.

SNDL Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SNDL Inc. reported revenue of $465M and earnings per share (EPS) of $-0.50. Net income for the quarter was $-67M. Gross margin was -17.1%. Operating income came in at $-80M.

In FY 2024, SNDL Inc. reported revenue of $465M and earnings per share (EPS) of $-0.50. Net income for the quarter was $-67M. Gross margin was -17.1%. Revenue grew -32.5% year-over-year compared to FY 2023. Operating income came in at $-80M.

In FY 2023, SNDL Inc. reported revenue of $689M. Net income for the quarter was $-134M. Gross margin was 20.9%. Revenue grew 30.8% year-over-year compared to FY 2022. Operating income came in at $-94M.

In FY 2022, SNDL Inc. reported revenue of $526M. Net income for the quarter was $-275M. Gross margin was 19.7%. Revenue grew 1098.1% year-over-year compared to FY 2021. Operating income came in at $-185M.

Over the past 7 quarters, SNDL Inc. has demonstrated a growth trajectory, with revenue expanding from $49M to $465M. Investors analyzing SNDL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SNDL Dividend Yield and Income Analysis

SNDL Inc. (SNDL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SNDL Momentum and Technical Analysis Profile

SNDL Inc. (SNDL) has a momentum factor score of 25/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 55/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 63/100 reflects moderate short selling activity.

SNDL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SNDL Inc. (SNDL) ranks #457 out of 838 stocks based on the Blank Capital composite score. This places SNDL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SNDL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SNDL vs S&P 500 (SPY) comparison to assess how SNDL Inc. stacks up against the broader market across all factor dimensions.

SNDL Next Earnings Date

No upcoming earnings date has been announced for SNDL Inc. (SNDL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SNDL? — Investment Thesis Summary

The quantitative profile for SNDL Inc. suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Momentum is weak at 25/100, a headwind for near-term performance.

In summary, SNDL Inc. (SNDL) earns a Reduce rating with a composite score of 35.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SNDL stock.

Related Resources for SNDL Investors

Explore more research and tools: SNDL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SNDL head-to-head with peers: SNDL vs AZN, SNDL vs SLGL, SNDL vs VMD.